BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma

被引:30
作者
Tang, SC
Beck, J
Murphy, S
Chernenko, G
Robb, D
Watson, P
Khalifa, M
机构
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
[2] McGill Univ, Dept Pathol, Montreal, PQ, Canada
[3] Mem Univ Newfoundland, St John, NF, Canada
[4] Univ Manitoba, Fac Med, Dept Pathol, Winnipeg, MB, Canada
[5] Univ Toronto, Fac Med, Dept Lab Med & Pathol, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
BAG-1; Bcl-2; breast cancer; p53; prognostic factors;
D O I
10.1023/B:BREA.0000019951.32001.93
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BAG-1, a recently identified anti-apoptotic protein, is overexpressed in the majority of invasive breast carcinomas. Overexpression of BAG-1 is important for both multi-step oncogenesis and resistance of cancer cells to apoptosis induced by DNA-damaging alkylating agents. BAG-1 protein species are localized differentially; nuclear expression may be associated with a shorter disease-free and overall survival in early stage breast cancer, while cytoplasmic expression has been associated with longer survival in non-small cell lung cancer. Growing evidence suggests that Bcl-2 and p53 are also involved in the oncogenesis of breast cancer. Since BAG-1 interacts with Bcl-2 and is upregulated by mutant p53 in vitro, it would be interesting to determine if their expressions are correlated with each other and with other clinical prognostic factors in invasive breast cancer. To address this question we conducted a large scale retrospective study of BAG-1, Bcl-2 and p53 in 185 breast cancer patients. Our study again showed that BAG-1 is overexpressed in the majority of breast cancer patients. In addition, it demonstrated that the expression of BAG-1 correlates with that of Bcl-2, p53, differentiation, estrogen and progesterone receptors. Our clinical study supports the preclinical finding of the interaction between BAG-1 and Bcl-2, p53 and estrogen and progesterone receptors. Further experiments to explore the prognostic and therapeutic role of BAG-1 in breast cancer are warranted.
引用
收藏
页码:203 / 213
页数:11
相关论文
共 60 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   BAG-1 and Bcl-2 in IL-2 signaling [J].
Adachi, M ;
Torigoe, T ;
Takayama, S ;
Imai, K .
LEUKEMIA & LYMPHOMA, 1998, 30 (5-6) :483-491
[3]   Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain [J].
Adachi, M ;
Sekiya, M ;
Torigoe, T ;
Takayama, S ;
Reed, JC ;
Miyazaki, T ;
Minami, Y ;
Taniguchi, T ;
Imai, K .
BLOOD, 1996, 88 (11) :4118-4123
[4]   HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death [J].
Bardelli, A ;
Longati, P ;
Albero, D ;
Goruppi, S ;
Schneider, C ;
Ponzetto, C ;
Comoglio, PM .
EMBO JOURNAL, 1996, 15 (22) :6205-6212
[5]   P53, Apoptosis, and Breast Cancer [J].
Barnes, Diana M. ;
Camplejohn, Richard S. .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1996, 1 (02) :163-175
[6]  
Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.0.CO
[7]  
2-1
[8]   Clinical studies of p53 in treatment and benefit of breast cancer patients [J].
Bergh, J .
ENDOCRINE-RELATED CANCER, 1999, 6 (01) :51-59
[9]   High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers [J].
Brimmell, M ;
Burns, JS ;
Munson, P ;
McDonald, L ;
O'Hare, MJ ;
Lakhani, SR ;
Packham, G .
BRITISH JOURNAL OF CANCER, 1999, 81 (06) :1042-1051
[10]   Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line [J].
Chen, J ;
Xiong, JY ;
Liu, HY ;
Chernenko, G ;
Tang, SC .
ONCOGENE, 2002, 21 (46) :7050-7059